11.15
Keros Therapeutics Inc stock is traded at $11.15, with a volume of 415.45K.
It is up +0.46% in the last 24 hours and up +0.00% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$11.08
Open:
$11.34
24h Volume:
415.45K
Relative Volume:
0.27
Market Cap:
$452.06M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.1735
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
+3.16%
1M Performance:
+0.00%
6M Performance:
-76.71%
1Y Performance:
-83.83%
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
KROS
Keros Therapeutics Inc
|
11.14 | 452.06M | 0 | -168.05M | -146.15M | -5.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.10 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
687.63 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
633.30 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.11 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
112.75 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
Dec-16-24 | Reiterated | Oppenheimer | Outperform |
Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
Nov-05-24 | Initiated | Jefferies | Buy |
Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Sep-23-24 | Initiated | Guggenheim | Buy |
Jun-25-24 | Initiated | Oppenheimer | Outperform |
Feb-21-24 | Initiated | William Blair | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Jul-31-23 | Initiated | Wedbush | Outperform |
Jul-26-23 | Initiated | BofA Securities | Buy |
Feb-14-23 | Initiated | Cowen | Outperform |
Oct-18-22 | Initiated | Truist | Buy |
Jul-26-22 | Initiated | BTIG Research | Buy |
Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
May-04-20 | Initiated | H.C. Wainwright | Buy |
May-04-20 | Initiated | Jefferies | Buy |
May-04-20 | Initiated | Piper Sandler | Overweight |
May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
(KROS) On The My Stocks Page - Stock Traders Daily
Q1 EPS Forecast for Keros Therapeutics Lifted by Analyst - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
FY2026 EPS Estimate for Keros Therapeutics Lifted by Analyst - MarketBeat
What is William Blair’s Forecast for KROS Q1 Earnings? - Defense World
Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
Y Intercept Hong Kong Ltd Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00 - Defense World
Q2 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
Keros Therapeutics CEO to Speak at Major Conferences - TipRanks
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
When and Where to Hear Keros Therapeutics' Latest Updates: CEO's March Conference Schedule - StockTitan
Wells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $40.00 - MarketBeat
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns - TipRanks
Keros Therapeutics stock target cut to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Analyst Expectations For Keros Therapeutics's Future - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Keros Therapeutics, Inc. SEC 10-K Report - TradingView
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year - TipRanks
How Keros Therapeutics Secured Funding Until 2029 Despite Widening Losses - StockTitan
Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Growth in Short Interest - MarketBeat
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Institutional owners may consider drastic measures as Keros Therapeutics, Inc.'s (NASDAQ:KROS) recent US$55m drop adds to long-term losses - Simply Wall St
Research Analysts Issue Forecasts for KROS FY2028 Earnings - MarketBeat
There is no way Keros Therapeutics Inc (KROS) can keep these numbers up - SETE News
Examining the Potential Price Growth of Keros Therapeutics Inc (KROS) - Knox Daily
Leerink Partnrs Has Positive Outlook of KROS FY2028 Earnings - Defense World
(KROS) Proactive Strategies - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KROS Shares Experience Surge in Value - Knox Daily
24,493 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by SG Americas Securities LLC - MarketBeat
Examining Keros Therapeutics Inc (KROS) stock is warranted - US Post News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Cantor Fitzgerald Downgrades Keros Therapeutics Inc (KROS) to a Neutral from an Overweight - Knox Daily
An analyst sees good growth prospects for Keros Therapeutics Inc (KROS) - SETE News
SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Exchange Traded Concepts LLC Makes New $99,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):